Fig. 1: Reduced KMT2C activity is associated with more aggressive clinical characteristics.

a Box plots indicating relative KMT2C expression with respect to tumor grade and stage in our cohort. The correlation of KMT2C expression with tumor grade and stage was assessed by Mann-Whitney U and Kruskal-Wallis tests, respectively. For pairwise comparisons between tumor stages Mann-Whitney U test was used. ****p < 0.0001, ***p < 0.001, *p < 0.05. b Relative KMT2C expression with respect to tumor grade and stage in an independent published cohort²⁰. The geometrical mean of log2 values from 4 different probes was used and the significance was assessed by Mann-Whitney U test. c–e Kaplan-Meier survival curves of bladder cancer patients with respect to KMT2C expression levels. “n” refers to the number of patients and “events” refers to deaths or cases of disease recurrence, depending on the plot. For all plots, median was used as the cut-off between the two groups. OS overall survival, DFS disease-free survival, PFS progression-free survival, MS Median survival. p-value calculated by log-rank test. f Box and whisker plot (2.5-97.5 percentile) showing the levels of total and phosphorylated PDK1(Ser241) in TCGA bladder cancer patients⁷ with WT and mutant KMT2C. Outliers beyond the end of the whiskers are also indicated. Man-Whitney test was employed for statistical analysis. **p < 0.01; ns: not significant (p > 0.05).